Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and autoimmune diseases. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Program (Cell Type) Indication CAR Target(s) Research Preclinical Phase 1 Partner
CAR T-cell Product Candidates
FT819 Systemic Lupus Erythematosus CD19

 

FT825 Solid Tumors HER2

 

Undisclosed Solid Tumors Undisclosed

 

Ono Logo
FT836 Multiple Tumor Types MICA/B

 

Next gen iTs Multiple Therapeutic Areas Undisclosed

 

CAR NK Cell Product Candidates
FT522 B-cell Lymphoma CD19, 4-1BB

 

FT522 Autoimmunity CD19, 4-1BB

 

Next gen iNKs Multiple Therapeutic Areas Undisclosed

 

CAR T-cell Therapy

Program Indication CAR Targert(s) Phase
FT819 (iT) Systemic Lupus Erythematosus CD19 Ph 1
FT825 (iT) Solid tumors HER2 Ph 1
Undisclosed Solid Tumors Undisclosed PreClin
FT836 Multiple Tumor Types MICA/B PreClin
Next gen iTs Multiple Therapeutic Areas Undisclosed PreClin

CAR NK cell Therapy

Program Indication CAR Target(s) Phase
FT222 (iNK) B-cell Lymphoma D19, 4-1BB Ph 1
FT222 (iNK) Undisclosed CD19, 4-1BB Preclin
Next gen iNKs Multiple Therapeutic Areas Undisclosed Research

iPSC = induced pluripotent stem cell    iNK = iPSC-derived NK Cell    iT = iPSC-derived T cell    CAR = chimeric antigen receptor